Compass Therapeutics Provides Corporate Update We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer...

CD137 Antibodies Clinical Trials Market Opportunity Insight Delhi, March 21, 2023 (GLOBE NEWSWIRE) -- Advancement in cancer immunology and recent clinical evidence have suggested that there is an urgent need to move towards new immunotherapeutic approaches...

Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...